Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
1. A method of delivering an oligonucleotide to a subject, wherein the subject has facioscapulohumeral muscular dystrophy, the method comprising intravenously administering to the subject a complex that comprises an anti-transferrin receptor antibody covalently linked to a 5′ end or a 3′ end of an oligonucleotide,
wherein the anti-transferrin receptor antibody binds in the range of C89 to F760 of human transferrin receptor protein 1 (TfR1) having an amino acid sequence as set forth in SEQ ID NO: 1 and wherein the anti-transferrin receptor antibody does not specifically bind to the transferrin binding site of TfR1;
wherein the oligonucleotide comprises one or more modifications and a single strand that comprises a region of complementarity of at least 15 nucleotides in length to the nucleotide sequence as set forth in SEQ ID NO: 52, wherein the oligonucleotide is in the range of 15-35 nucleotides in length;
wherein the one or more modifications comprise a 2′-modified nucleoside selected from the group consisting of: a 2′-O-methyl nucleoside, a 2′-fluoro nucleoside, a 2′-O-methoxyethyl nucleoside, and 2′,4′-bridged nucleosides, and combinations thereof, and/or comprise a modified backbone selected from a backbone comprising one or more phosphorothioate linkages and a phosphorodiamidate morpholino backbone; and
wherein the oligonucleotide brings about degradation of DUX4 RNA in the muscle cell.
2. The method of claim 1 , wherein the region of complementarity is at least 20 nucleotides in length.
3. The method of claim 1 , wherein the oligonucleotide is covalently linked to a lysine in the anti-transferrin receptor antibody via a cleavable linker.
4. The method of claim 3 , wherein the cleavable linker comprises a valine-citrulline sequence.
5. The method of claim 3 , wherein the complex is obtained by a cycloaddition reaction between an azide and an alkyne to form a triazole.
6. The method of claim 4 , wherein prior to the cycloaddition reaction, the azide is covalently linked to the valine-citrulline sequence of the cleavable linker that is covalently linked to the oligonucleotide and the alkyne is provided in a bicyclononyne moiety that further covalently links to the anti-transferrin receptor antibody.
7. The method of claim 4 , wherein the cleavable linker further comprises one or more polyethylene glycol units.
8. The method of claim 1 , wherein the anti-transferrin receptor antibody binds to human TfR1 with a K D in a range of 10 −11 M to 10 −8 M.
9. The method of claim 1 , wherein the anti-transferrin receptor antibody is in the form of a ScFv, Fab fragment, Fab′ fragment, F(ab′)2 fragment, or Fv fragment.
10. The method of claim 1 , wherein the anti-transferrin receptor antibody is in the form of a Fab fragment.
11. The method of claim 1 , wherein the subject has one or more deletions of D4Z4 repeats in chromosome 4.
12. The method of claim 11 , wherein the subject has 10 or fewer D4Z4 repeats.
13. The method of claim 1 , wherein the muscle cell is a skeletal muscle cell, cardiac muscle cell, or smooth muscle cell.
14. The method of claim 1 , wherein the subject is human.
15. The method of claim 1 , wherein the subject is cynomolgus.
16. The method of claim 1 , wherein the region of complementarity is at least 16 nucleotides in length.
17. The method of claim 1 , wherein the region of complementarity is at least 17 nucleotides in length.
18. The method of claim 1 , wherein the region of complementarity is at least 18 nucleotides in length.
19. The method of claim 1 , wherein the region of complementarity is at least 19 nucleotides in length.
20. A method of delivering an oligonucleotide to a subject, wherein the subject has a muscular dystrophy associated with mutation of a repeat region, the method comprising intravenously administering to the subject a complex that comprises an anti-transferrin receptor antibody covalently linked to a 5′ end or a 3′ end of an oligonucleotide,
wherein the anti-transferrin receptor antibody binds in the range of C89 to F760 of human transferrin receptor protein 1 (TfR1) having an amino acid sequence as set forth in SEQ ID NO: 1 and wherein the anti-transferrin receptor antibody does not specifically bind to the transferrin binding site of TfR1;
wherein the oligonucleotide comprises one or more modifications and a single strand that comprises a region of complementarity of at least 15 nucleotides in length to an RNA encoded by a gene associated with the muscular dystrophy, wherein the mutation of the repeat region results in aberrant gene expression, wherein the oligonucleotide is in the range of 15-35 nucleotides in length;
wherein the one or more modifications comprise a 2′-modified nucleoside selected from the group consisting of: a 2′-O-methyl nucleoside, a 2′-fluoro nucleoside, a 2′-O-methoxyethyl nucleoside, and 2′,4′-bridged nucleosides, and/or comprise a modified backbone selected from a backbone comprising one or more phosphorothioate linkages and a phosphorodiamidate morpholino backbone; and
wherein the oligonucleotide brings about degradation of the RNA encoded by the gene associated with muscular dystrophy in the muscle cell.
21. The method of claim 20 , wherein the anti-transferrin receptor antibody comprises a CDRH1, a CDRH2, a CDRH3, a CDRL1, a CDRL2, and a CDRL3 of an antibody listed in Table 1.
22. The method of claim 20 , wherein the muscular dystrophy is facioscapulohumeral muscular dystrophy.
23. The method of claim 20 , wherein the muscular dystrophy is myotonic dystrophy.